Research indicates that dilated cardiomyopathy can be caused by the cumulative influence of potentially thousands of genes, not just one single genetic variant.
Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.